Copy to clipboard 
Proprio’s Paradigm AI guidance platform for surgery received its second major FDA 510(k) clearance to include intraoperative measurements. This is the first-ever technology that enables 3D, dynamic and segmental viewing of the anatomy, and marks the first time in history that surgeons will be able to measure success in real-time during surgery.
The announcement follows Proprio’s first FDA clearance for Paradigm in 2023.
Prior to this latest clearance, surgeons were not able to easily measure progress to their goals during surgery. To take measurements during a procedure, doctors would have to scrub out and back in between taking X-rays and CT scans, leading to significant delays while patients were under anesthesia and losing blood. As a result, surgeons would commonly choose to keep surgery moving without delay and had to rely on preoperative measurements for planning and postoperative measurements to determine if they achieved their goals.
Now, the Paradigm AI platform shares real-time progress against pre-operative plans with continuous, accurate measurements, and lets surgeons know when they have achieved their goals. Using real-time data to inform decisions during surgery can save patients from several more revision surgeries and significantly improve outcomes altogether.
Proprio’s real-time intraoperative measurements add to a trove of surgical data. With a comprehensive, multimodal dataset that has a clear view of surgery and is clean, labeled and continuously refined with surgeon expertise in the loop, Proprio claims to offer the most complete and factual view of surgery — creating new opportunities for training and clinical research.
“Evolving from highly educated guesswork to data-driven certainty with intraoperative measurements is game-changing,” said Gabriel Jones, CEO and Co-Founder of Proprio. “Working with the best surgeons, Proprio is reshaping what’s possible in surgery and transforming healthcare with AI — not just automating tasks, but improving cognitive calibration, optimizing workflows for operating teams, robotics, and devices, while reducing the risk of adverse events. Our mission is to set a new standard of care that is 10 times more accessible and dramatically improves lives. Giving surgeons the visibility and data they need precisely when they need it is a huge leap forward in achieving our goals.”
Source: Proprio
Proprio's Paradigm AI guidance platform for surgery received its second major FDA 510(k) clearance to include intraoperative measurements. This is the first-ever technology that enables 3D, dynamic and segmental viewing of the anatomy, and marks the first time in history that surgeons will be able to measure success in real-time during...
Proprio’s Paradigm AI guidance platform for surgery received its second major FDA 510(k) clearance to include intraoperative measurements. This is the first-ever technology that enables 3D, dynamic and segmental viewing of the anatomy, and marks the first time in history that surgeons will be able to measure success in real-time during surgery.
The announcement follows Proprio’s first FDA clearance for Paradigm in 2023.
Prior to this latest clearance, surgeons were not able to easily measure progress to their goals during surgery. To take measurements during a procedure, doctors would have to scrub out and back in between taking X-rays and CT scans, leading to significant delays while patients were under anesthesia and losing blood. As a result, surgeons would commonly choose to keep surgery moving without delay and had to rely on preoperative measurements for planning and postoperative measurements to determine if they achieved their goals.
Now, the Paradigm AI platform shares real-time progress against pre-operative plans with continuous, accurate measurements, and lets surgeons know when they have achieved their goals. Using real-time data to inform decisions during surgery can save patients from several more revision surgeries and significantly improve outcomes altogether.
Proprio’s real-time intraoperative measurements add to a trove of surgical data. With a comprehensive, multimodal dataset that has a clear view of surgery and is clean, labeled and continuously refined with surgeon expertise in the loop, Proprio claims to offer the most complete and factual view of surgery — creating new opportunities for training and clinical research.
“Evolving from highly educated guesswork to data-driven certainty with intraoperative measurements is game-changing,” said Gabriel Jones, CEO and Co-Founder of Proprio. “Working with the best surgeons, Proprio is reshaping what’s possible in surgery and transforming healthcare with AI — not just automating tasks, but improving cognitive calibration, optimizing workflows for operating teams, robotics, and devices, while reducing the risk of adverse events. Our mission is to set a new standard of care that is 10 times more accessible and dramatically improves lives. Giving surgeons the visibility and data they need precisely when they need it is a huge leap forward in achieving our goals.”
Source: Proprio
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
